4Maejima K,Nakano S,Himeno M,et al. Increased basal levels of plasma nitric oxide in type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications, 2001,15 (3) : 135 - 143.
5Mather K, Anderson TJ, Verma S. Insulin action in the vasculature. physiology and pathophysiology. J Vase Res, 2001,38(5) : 415 - 422.
6Wesson DE, Simon J, Green DF. Reduced extracellular pH increases endothelin- 1 secretion by human renal micmvascular endothelial cells. J Clin Invest, 1998,101 (3) : 578 - 583.
7Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non- diabetic renal disease. Nephrol Dial Transplant,2004,19(4) :778 - 781.
9Douglas SA, Ohlstein EH. Signal transduction mechanisms mediating the vascular actions of endothelin. J Vase Res, 1997, 34 (3) :152- 164.
10Jiang J, Zhang L, Macleod KM, et al. Effect of chronic endothelin blockade on PKC isoform distribution in mesenteric arteries from diabetic rats. Mol Cell Biochem, 2005,28 ( 1 - 2) :69 - 75.
5Yao J,Morioka T,Li B,et al.Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells[J].Am J Physiol Renal Physiol,2001,280(4):F628-635.
6Gqmez GC,Gonzalez C,Egido J.Evidence for a specific IgA receptor in rat and human mesangial cells[J].J Immunol,1993,151:7172-7279.
7Boffa JJ,Tharaux PL,Dussaule JC,et al.Regression of renal vascular fibrosis by endothelin receptor antagonism[J].Hypertension,2001,37(22):490-496.
8Gomez-Garre D,Largo R,Liu XH,et al.An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis[J].Kidney Int,1996,50(3):962-972.
9Gomez-Garre D,Ruiz-Ortega M,Ortego M,et al.Effects and interactions of endothelin-1 and angiotensin Ⅱ on matrix protein expression and synthesis and mesangial cell growth[J].Hypertension,1996,27(4):885-892.
